Neil Shah, MD, PhD

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
shah_neil

Associate Professor, Department of Medicine (Hematology/Oncology), UCSF
Program Leader, Hematopoietic Malignancies Program, UCSF Helen Diller Family Comprehensive Cancer Center

Edward S. Ageno Distinguished Professorship in Hematology/Oncology, UCSF

nshah@medicine.ucsf.edu

Phone: (415) 353-2421 (medical appts); (415) 514-0269 (academic issues)
Box 1270, UCSF
San Francisco, CA 94143-1270

View on UCSF Profiles


Additional Websites


Education

University of California, Berkeley, BS,1984, Genetics
University of California, Los Angeles, PhD, 1992, Microbiology & Molecular Genetics
University of California, Los Angeles, MD, 1996, Medicine


Professional Experience

  • 1984-1987
    Staff Research Associate, University of California, Los Angeles (UCLA), laboratory of Irvin S.-Y. Chen
  • 1987-1992
    Graduate Student Researcher, UCLA, laboratory of Owen N. Witte
  • 1996-1998
    Internship and Residency, UCLA School of Medicine
  • 1998-2000
    Clinical part of Fellowship in Hematology/Oncology, UCLA School of Medicine
  • 2000-2003
    Postdoctoral Fellow, UCLA, laboratory of Charles L. Sawyers
  • 2003-2004
    Clinical Instructor, Division of Hematology/Oncology, UCLA School of Medicine
  • 2004-2006
    Visiting Assistant Professor, Division of Hematology/Oncology, UCLA School of Medicine
  • 2006-2013
    Assistant Professor, Division of Hematology/Oncology, University of California, San Francisco (UCSF) School of Medicine
  • 2013-present
    Associate Professor, Division of Hematology/Oncology, University of California, San Francisco (UCSF) School of Medicine

Honors & Awards

  • 1989-1991
    National Institutes of Health Predoctoral Award in Tumor Cell Biology
  • 1995
    Alpha Omega Alpha Medical Student Research Prize
  • 1995-2003
    UCLA Specialty Training and Advanced Research (STAR) Award
  • 2001-2004
    Leukemia and Lymphoma Society Career Development Award for Fellows
  • 2003-2005
    NIH K12 Award in Clinical Pharmacology
  • 2004-2007
    Leukemia and Lymphoma Society Career Development Award for Special Fellows
  • 2006-2009
    Doris Duke Charitable Foundation Clinical Scientist Development Award
  • 2009-2014
    Leukemia and Lymphoma Society Scholar in Clinical Research Award

Selected Publications

  1. Lilly MB, Ottmann OG, Shah NP, Larson RA, Reiffers JJ, Ehninger G, Müller MC, Charbonnier A, Bullorsky E, Dombret H, Brigid Bradley-Garelik M, Zhu C, Martinelli G. Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study. Am J Hematol. 2010 Mar; 85(3):164-70.
    View on PubMed
  2. Shah NP, Kim DW, Kantarjian H, Rousselot P, Llacer PE, Enrico A, Vela-Ojeda J, Silver RT, Khoury HJ, Müller MC, Lambert A, Matloub Y, Hochhaus A. Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib. Haematologica. 2010 Feb; 95(2):232-40.
    View on PubMed
  3. Paquette RL, Nicoll J, Chalukya M, Gondek L, Jasek M, Sawyers CL, Shah NP, Maciejewski J. Clonal hematopoiesis in Philadelphia chromosome-negative bone marrow cells of chronic myeloid leukemia patients receiving dasatinib. Leuk Res. 2010 Jun; 34(6):708-13.
    View on PubMed
  4. Kantarjian H, Pasquini R, Lévy V, Jootar S, Holowiecki J, Hamerschlak N, Hughes T, Bleickardt E, Dejardin D, Cortes J, Shah NP. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R). Cancer. 2009 Sep 15; 115(18):4136-47.
    View on PubMed
  5. Seeliger MA, Ranjitkar P, Kasap C, Shan Y, Shaw DE, Shah NP, Kuriyan J, Maly DJ. Equally potent inhibition of c-Src and Abl by compounds that recognize inactive kinase conformations. Cancer Res. 2009 Mar 15; 69(6):2384-92.
    View on PubMed
  6. Shah NP, Kasap C, Weier C, Balbas M, Nicoll JM, Bleickardt E, Nicaise C, Sawyers CL. Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis. Cancer Cell. 2008 Dec 9; 14(6):485-93.
    View on PubMed
  7. Shah NP, Kantarjian HM, Kim DW, Réa D, Dorlhiac-Llacer PE, Milone JH, Vela-Ojeda J, Silver RT, Khoury HJ, Charbonnier A, Khoroshko N, Paquette RL, Deininger M, Collins RH, Otero I, Hughes T, Bleickardt E, Strauss L, Francis S, Hochhaus A. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol. 2008 Jul 1; 26(19):3204-12.
    View on PubMed
  8. Hochhaus A, Baccarani M, Deininger M, Apperley JF, Lipton JH, Goldberg SL, Corm S, Shah NP, Cervantes F, Silver RT, Niederwieser D, Stone RM, Dombret H, Larson RA, Roy L, Hughes T, Müller MC, Ezzeddine R, Countouriotis AM, Kantarjian HM. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia. 2008 Jun; 22(6):1200-6.
    View on PubMed
  9. Shah NP. Advanced CML: therapeutic options for patients in accelerated and blast phases. J Natl Compr Canc Netw. 2008 Mar; 6 Suppl 2:S31-S36.
    View on PubMed
  10. Shah NP. Progressive thoughts about progressive disease. Clin Cancer Res. 2007 Sep 15; 13(18 Pt 1):5229-31.
    View on PubMed
  11. Shah NP. Dasatinib. Drugs Today (Barc). 2007 Jan; 43(1):5-12.
    View on PubMed
  12. Shah NP. Medical management of CML. Hematology Am Soc Hematol Educ Program. 2007; 371-5.
    View on PubMed
  13. Hochhaus A, Kantarjian HM, Baccarani M, Lipton JH, Apperley JF, Druker BJ, Facon T, Goldberg SL, Cervantes F, Niederwieser D, Silver RT, Stone RM, Hughes TP, Muller MC, Ezzeddine R, Countouriotis AM, Shah NP. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood. 2007 Mar 15; 109(6):2303-9.
    View on PubMed
  14. Young MA, Shah NP, Chao LH, Seeliger M, Milanov ZV, Biggs WH, Treiber DK, Patel HK, Zarrinkar PP, Lockhart DJ, Sawyers CL, Kuriyan J. Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680. Cancer Res. 2006 Jan 15; 66(2):1007-14.
    View on PubMed
  15. Michor F, Hughes TP, Iwasa Y, Branford S, Shah NP, Sawyers CL, Nowak MA. Dynamics of chronic myeloid leukaemia. Nature. 2005 Jun 30; 435(7046):1267-70.
    View on PubMed
  16. Shah NP. Loss of response to imatinib: mechanisms and management. Hematology Am Soc Hematol Educ Program. 2005; 183-7.
    View on PubMed
  17. Chu S, Xu H, Shah NP, Snyder DS, Forman SJ, Sawyers CL, Bhatia R. Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment. Blood. 2005 Mar 1; 105(5):2093-8.
    View on PubMed
  18. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science. 2004 Jul 16; 305(5682):399-401.
    View on PubMed
  19. Shah NP, Sawyers CL. Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias. Oncogene. 2003 Oct 20; 22(47):7389-95.
    View on PubMed
  20. Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, Kuriyan J, Sawyers CL. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell. 2002 Aug; 2(2):117-25.
    View on PubMed

Go to UCSF Profiles, powered by CTSI